My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

2.650 +0.160 (+6.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,021,020
Open 2.490
Bid (Size) 2.640 (26)
Ask (Size) 2.650 (101)
Prev. Close 2.490
Today's Range 2.490 - 2.680
52wk Range 1.285 - 7.850
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Annexon Biosciences to Participate in Upcoming September Investor Conferences
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire

Performance

YTD
-51.8%
-51.8%
1 Month
+12.8%
+12.8%
3 Month
+8.6%
+8.6%
6 Month
-3.6%
-3.6%
1 Year
-63.0%
-63.0%

More News

Read More
Annexon Narrows Loss in Fiscal Q2
Via The Motley Fool
Topics Intellectual Property
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Thursday's session: gap up and gap down stocks
Via Chartmill
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder
Via Benzinga
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire

Frequently Asked Questions

Is Annexon, Inc. - common stock publicly traded?
Yes, Annexon, Inc. - common stock is publicly traded.
What exchange does Annexon, Inc. - common stock trade on?
Annexon, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Annexon, Inc. - common stock?
The ticker symbol for Annexon, Inc. - common stock is ANNX on the Nasdaq Stock Market
What is the current price of Annexon, Inc. - common stock?
The current price of Annexon, Inc. - common stock is 2.650
When was Annexon, Inc. - common stock last traded?
The last trade of Annexon, Inc. - common stock was at 09/16/25 04:00 PM ET
What is the market capitalization of Annexon, Inc. - common stock?
The market capitalization of Annexon, Inc. - common stock is 126.47M
How many shares of Annexon, Inc. - common stock are outstanding?
Annexon, Inc. - common stock has 126M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.